Global Information
회사소개 | 문의 | 비교리스트

세계의 치루 치료 시장(2020-2026년)

Global Anal Fistula Therapeutics Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949663
페이지 정보 영문
가격
US $ 3,600 ₩ 4,243,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,658,000 Printable PDF (Enterprise License)


세계의 치루 치료 시장(2020-2026년) Global Anal Fistula Therapeutics Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 치루 치료 시장은 예측 기간 중 대폭 성장할 것으로 추정되고 있습니다. IBD의 높은 이환율은 주로 시장의 성장을 촉진하고 있습니다. 새로운 비외과적 대체안은 시장 성장의 기회를 제공할 것으로 기대되고 있습니다. 피브린 접착제와 알로피셀(darvadstrocel)은 치루의 치료를 위해 시장에서 입수 가능한 비외과적 대체안입니다. 피브린 접착제는 환자가 전신마취하에 있을 때 외과의가 접착제를 누공에 주입합니다. 이 접착제는 누를 밀봉하고, 이것이 치유를 지원합니다. 일반적으로 단순루의 누공 절개술에 비해 효과가 낮습니다.

그 결과는 장기간 지속하지 않을 가능성이 있습니다. 그러나 항문의 괄약근을 통과하는 누(fistulas)에서는 컷이 필요없으므로 누를 대신하는 경우가 있습니다. 알로피셀(darvadstrocel)은 누공이 적어도 1개의 전통적 또는 생물학적 요법에 대해 불충분한 반응을 나타낼 경우, 비활동성/경도 활동성 관강 크론병을 앓고 있는 성인 환자의 복잡한 항문 주위 누공을 치료하는 최초의 줄기세포 요법입니다. 보다 비외과적 대체안이 향후 도입될 것으로 예상되며, 이것은 시장의 성장을 위한 중요한 기회를 제공할 것입니다.

지역적으로 2019년에 북미는 IBD의 만연과 지역에서의 상당한 건강 인식 덕분에 시장에서 최대 점유율을 유지했습니다. Center for Disease Control and Prevention(CDC)에 따르면 2015년 미국 성인의 약 1.3%(300만 명)가 IBD(궤양성 대장염 또는 크론병 중 하나)로 진단되었다고 보고되고 있습니다. 궤양성 대장염보다 크론병에서 가장 빈번히 볼 수 있는 IBD의 일반적인 합병증이며, 장기가 염증을 일으키거나 부상을 입으면 누를 형성할 가능성이 높아집니다. 따라서 IBD 보급의 증가는 시장의 성장에 기여하고 있습니다.

세계의 치루 치료 시장에 대해 조사했으며, 시장의 개요와 치료별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재의 시장 동향
  • 룰과 규칙

제3장 경쟁 구도

  • 회사 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Medtronic plc
    • Karl Storz SE&Co. KG
    • Cook Group Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • Signum Surgical Ltd.

제4장 시장 결정요인

  • 동기
  • 억제요인
  • 시장 기회

제5장 시장 세분화

  • 치료별 세계의 치루 치료 시장
    • 외과적
    • 비외과적
  • 용도별 세계의 치루 치료 시장
    • 괄약근간루(Intersphincteric Fistula)
    • 경괄약근루(Transsphincteric Fistula)
    • 괄약근루(Suprasphincteric Fistula)
    • 기타
  • 최종사용자별 세계의 치루 치료 시장
    • 병원
    • 외래 수술 센터
    • 기타

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • Medtronic plc
  • Cook Group Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Karl Storz SE & Co. KG
  • Biolitec AG
  • Pfizer Inc.
  • Becton, Dickinson and Co.
  • GEM S.r.l.
  • TiGenix NV
  • W. L. Gore & Associates, Inc.
  • AstraZeneca plc
  • Agency for Medical Innovations(A.M.I.) GmbH
  • Signum Surgical Ltd.
  • Novartis International AG
  • Assembly Biosciences, Inc.
  • Ovesco Endoscopy AG
KSA 20.08.13

LIST OF TABLES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 2. GLOBAL SURGICAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL NON-SURGICAL ANAL FISTULA THERAPEUTICS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 5. GLOBAL INTERSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL TRANSSPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL SUPRASPHINCTERIC FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHER ANAL FISTULA THERAPEUTICS APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL ANAL FISTULA THERAPEUTICS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 10. GLOBAL ANAL FISTULA THERAPEUTICS IN AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL ANAL FISTULA THERAPEUTICS IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 17. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 19. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. EUROPEAN ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
  • 3. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 4. GLOBAL ANAL FISTULA THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. ROE ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 17. REST OF THE WORLD ANAL FISTULA THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)

Global Anal Fistula Therapeutics Market Size, Share & Trends Analysis Report, By Treatment (Surgical and Non-Surgical), By Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others) and Forecast, 2020-2026

The global anal fistula therapeutics market is estimated to grow significantly during the forecast period. The significant prevalence of IBD is primarily driving the growth of the market. Emerging non-surgical alternatives is expected to offer an opportunity for market growth. Fibrin glue and Alofisel (darvadstrocel) are the non-surgical alternatives available in the market for the treatment of anal fistula. Fibrin glue involves injecting a glue by the surgeon into the fistula when the patient is under general anaesthetic. This glue enables to seal the fistula and supports it to heal. It is usually less effective compared to fistulotomy for simple fistulas.

Its results may not last for a longer period; however, it may be a helpful alternative for fistulas that pass through the anal sphincter muscles as the cut is not required there. Alofisel (darvadstrocel) is the first stem cell therapy to treat complex perianal fistulas in adult patients suffering from nonactive/mildly active luminal Crohn's disease when fistulas have shown an insufficient response to at least one traditional or biologic therapy. More non-surgical alternatives are expected to be introduced in the future, which will likely present a significant opportunity for the growth of the market.

Geographically, in 2019, North America held the largest share in the market owing to the rising prevalence of IBD and considerable health awareness in the region. As per the Centers for Disease Control and Prevention (CDC), in 2015, nearly 1.3% of the US adults (3 million) were reported being diagnosed with IBD (either ulcerative colitis or Crohn's disease). Increased chances of developing fistulas occur when the organ becomes inflamed or injured, which is a common complication of IBD, found most frequently in Crohn's disease than ulcerative colitis. Therefore, the rising prevalence of IBD is contributing to the growth of the market.

Some key players in the market include Medtronic plc, Karl Storz SE & Co. KG, Cook Group Inc., Takeda Pharmaceutical Co. Ltd., and Signum Surgical Ltd. Medtronic offers Permacol collagen paste, which is a minimally invasive treatment for anal fistula. It is made of porcine dermal, acellular collagen suspended in saline. It may be utilized as a single treatment alternative or in combination with other treatment including the ligation of intersphincteric fistula tract (LIFT) technique. Signum Surgical developed the BioHealx device, for improvement in surgical procedures to fulfil all identified essential clinical requirements for reliable healing of heal anal fistulas.

Research Methodology

The market study of the global anal fistula therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anal Fistula Therapeutics Market Research and Analysis by Treatment
  • Global Anal Fistula Therapeutics Market Research and Analysis by Application
  • Global Anal Fistula Therapeutics Market Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global anal fistula therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anal fistula therapeutics market.
  • Insights about market determinants, which are stimulating the global anal fistula therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Medtronic plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Karl Storz SE & Co. KG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Cook Group Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Takeda Pharmaceutical Co. Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Signum Surgical Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Anal Fistula Therapeutics Market by Treatment
    • 5.1.1. Surgical
    • 5.1.2. Non-Surgical
  • 5.2. Global Anal Fistula Therapeutics Market by Application
    • 5.2.1. Intersphincteric Fistula
    • 5.2.2. Transsphincteric Fistula
    • 5.2.3. Suprasphincteric Fistula
    • 5.2.4. Others
  • 5.3. Global Anal Fistula Therapeutics Market by End-User
    • 5.3.1. Hospitals
    • 5.3.2. Ambulatory Surgical Centers
    • 5.3.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Medtronic plc
  • 7.2. Cook Group Inc.
  • 7.3. Takeda Pharmaceutical Co. Ltd.
  • 7.4. Karl Storz SE & Co. KG
  • 7.5. Biolitec AG
  • 7.6. Pfizer Inc.
  • 7.7. Becton, Dickinson and Co.
  • 7.8. GEM S.r.l.
  • 7.9. TiGenix NV
  • 7.10. W. L. Gore & Associates, Inc.
  • 7.11. AstraZeneca plc
  • 7.12. Agency for Medical Innovations (A.M.I.) GmbH
  • 7.13. Signum Surgical Ltd.
  • 7.14. Novartis International AG
  • 7.15. Assembly Biosciences, Inc.
  • 7.16. Ovesco Endoscopy AG
Back to Top
전화 문의
F A Q